The Development & Approval of Enhertu in Patients with Unresectable or Metastatic HER2-positive Breast Cancer

Time: 9:40 am
day: Day One


• Outlining the pre-clinical profile and mechanism of action of Enhertu ([Fam-] trastuzumab deruxtecan, DS-8201a, T-DXd)
• Reviewing clinical development leading to the approval of Enhertu
• Understanding the current development status of Enhertu